lower replacement rate of Medpor-coated compared to convention tubes(3.8 *vs* 26%) is seen to be at the expense of increased conjunctival overgrowth (23 *vs* 5.7%), and the overall rate of complications is therefore in fact comparable with conventional tubes. Medpor-coated tubes fail even to meet two of the key features of an ideal tube proposed by the authors (easy to insert and removable for cleaning if necessary). They appear to have little to recommend them.

References

- Fan X, Bi X, Fu Y, Zhou H. The use of Medpor-coated tear drainage tube in conjunctivodacryocystorhinostomy. *Eye* 2008; 22: 1148–1153.
- 2 Jones L. Conjunctivodacryocystorhinostomy. Am J Ophthalmol 1965; **59**: 773–783.
- 3 Rose G, Welham R. Jones lacrimal canalicular bypass tubes: twenty-five years' experience. *Eye* 1991; 5(part1): 13–19.

A Pearson

Department of Ophthalmology, Royal Berkshire Hospital, Berkshire, UK. E-mail: Andrew.pearson@royalberkshire.co.uk

Eye (2009) **23**, 2120–2121; doi:10.1038/eye.2008.417; published online 23 January 2009

Sir, Reply to Pearson

We all known that the ideal bypass tube should be hydrophobic, and there should be some rigidity, good biocompatibility, and less displacement or extrusion. It can be made up of various materials. Although the pyrex tube is successful in the majority of patients in relieving tearing, the main shortcoming of a Jones tube is extrusion. Using the Medpor tube as bypass tube, an improvement or complete relief of epiphora was achieved in most cases, and the tube extrusion or displacement was not seen in our study, although the rate of tube obstruction was higher than that reported in earlier studies.

Many doctors try to find an ideal bypass tube, but unfortunately all forms of artificial tear drainage replacement may be associated with either short- or longterm complications. It is still a hard and challenging work for all ophthalmologists.

X Fan, X Bi, Y Fu and H Zhou

Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, Shanghai, P R China E-mail: fanxg@sh163.net

Eye (2009) **23**, 2121; doi:10.1038/eye.2008.419; published online 23 January 2009

Sir,

Correspondence to case report titled: use of pegaptanib in the treatment of vitreous haemorrhage in idiopathic retinal vasculitis

I thank the authors for this interesting case report published recently.¹ There are a few questions that need to be addressed including systemic work-up. The 'vague' nature of his presentation may have indicated a detailed medical history and referral to the physicians. Abdominal symptoms could indicate either liver or renal dysfunction and in such cases routine blood and urine tests to look for abnormal liver function tests and proteinuria as well as abdominal ultrasound are justified.

Although Eales disease is a diagnosis of exclusion, a history of contact with persons with active-treated tuberculosis and travel in 'at risk' areas needs to be elucidated.² Systemic tuberculosis in an important condition to exclude and immunological tests such as the Mantoux test have a tendency to give variable results.³

We have previous experience of a case of a 25-year Caucasian man who presented with similar ocular symptoms and signs. His disease followed an aggressive course despite immunosuppressive medical therapy, laser treatment and vitreoretinal surgery. Our patient had abnormal liver function tests and proteinuria consistent with wide-spread tissue involvement with a negative Mantoux test. Prompt referral to the physicians following medical investigations with tuberculosis immunospot test demonstrated reactivity against Mycobacterium tuberculosis with significant response to triple therapy.4 We therefore suggest early referral to physicians in those patients with ischaemic vasculitis and systemic symptoms to exclude extrapulmonary tuberculosis as demonstrated in our case. Anti-VEGF agents have a specific activity to reduce oedema and inhibit angiogenesis and therefore therapy in the published case could have halted acute progression; however, it is possible that the disease process may have stabilized and resolved during the follow-up period.5

References

- Mitry D, Schmoll C, Hegde V, Borooah S, Singh J, Bennett H. Use of pegaptanib in the treatment of vitreous haemorrhage in idiopathic retinal vasculitis. *Eye* 2008; 22(11): 1449–1450.
- 2 Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, Ramakrishnan S. Eales disease—an update. *Surv Ophthalmol* 2002; **47**(3): 197–214.
- 3 Singh D, Sutton C, Woodcock A. Tuberculin test measurement: variability due to the time of reading. *Chest* 2002; **122**(4): 1299–1301.
- 4 Kim SH, Choi SJ, Kim HB, Kim NJ, Oh MD, Choe KW. Diagnostic usefulness of a T-cell based assay for extrapulmonary tuberculosis. *Arch Intern Med* 2007; **167**(20): 2255–2259.
- 5 Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. *Curr Opin Ophthalmol* 2007; 18(6): 502–508.